EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Efficacy and Safety of Argatroban as an Adjunct to Antiplatelet Therapy in Ischemic Stroke: An Updated Systematic Review and Meta-analysis

Wirksamkeit und Sicherheit von Argatroban als Zusatz zu einer Thrombozytenaggregationshemmung bei ischämischem Schlaganfall: aktualisierte systematische Übersicht und Metaanalyse

Syeda Takreem Fatima, Ahmed Raza, Abdullah Javed, Shabnam Ijaz, Mishaal Noor, Syeda Duaa Uzair, Abdul Raheem Malik, Rana Ali Mustafa, Safi Ur Rehman Daim

European Journal of Clinical Pharmacology · 2026-11 · 82 (11)

DOI: 10.1007/s00228-026-04203-7 ↗

Auf einen Blick

17 Studien zeigen: Argatroban verbesserte mRS 0–2 nicht signifikant und senkte die Kompositblutung nicht. END nahm ab; bei RCTs zeigte sich ein erhöhtes Blutungsrisiko.

Fragestellung

Wie wirksam und sicher ist Argatroban zusätzlich zu einer Thrombozytenaggregationshemmung bei akutem ischämischem Schlaganfall im Vergleich zur Kontrolle?

Methode

Systematische Übersicht und Metaanalyse; Suche in PubMed und Scopus; random-effects model; Bewertung mit GRADE.

Ergebnisse

17 Studien mit 51.703 Patient:innen in der Argatroban- und 18.759 in der Kontrollgruppe. mRS 0–2: RR 1,03 (95 %-KI 0,97–1,10); Kompositblutung: RR 1,10 (95 %-KI 0,98–1,23); END: RR 0,48 (95 %-KI 0,30–0,75); mRS 0–1: RR 1,22 (95 %-KI 1,01–1,48).

Einschränkungen

Subgruppenanalyse nur für RCTs zeigte erhöhtes Risiko für Komposit- und intrakranielle Blutung. GRADE der RCT-Daten reichte von sehr niedrig bis hoch.

Schlussfolgerung der Autor:innen

Argatroban als Zusatz zur Thrombozytenaggregationshemmung verbesserte das Gesamt-Outcome (mRS 0–2) nicht und verringerte die Kompositblutung nicht signifikant. Es erscheint sicher und kann END senken.

Kernaussagen

  • mRS 0–2: kein signifikanter Unterschied
  • END reduziert: RR 0,48 (95 %-KI 0,30–0,75)
  • RCT-Subgruppen mit mehr Komposit- und intrakranieller Blutung

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Metaanalyse in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 22.10.2026. Verfasst von Syeda Takreem Fatima und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Services Institute of Medical Sciences, Lahore, Pakistan. Hauptthemen laut MEDLINE: Arginine, Ischemic Stroke, Pipecolic Acids, Platelet Aggregation Inhibitors. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Acute ischemic stroke (AIS) is a life-threatening condition. Argatroban can limit thrombus progression and improve AIS’s functional outcomes. This study assessed the efficacy and safety of argatroban in combination with antiplatelet therapy compared to control.

Methods

PubMed and Scopus were searched. Primary outcomes were Modified Rankin Scale (mRS) 0–2 and composite hemorrhage; secondary outcomes included mRS (0–1), early neurological deterioration (END), change in National Institutes of Health Stroke Scale (NIHSS) score, mortality, intracranial and organ hemorrhage. A random-effects model was used, with risk ratios (RRs) reported for binary outcomes, while mean differences (MDs) for continuous outcomes at 95% confidence intervals (CI) and a p-value of 0.05.

Results

17 studies were included with a total of 51,703 and 18,759 patients in the argatroban and control group, respectively. The primary outcomes, mRS (0–2), and composite hemorrhage showed no significant difference between argatroban and control (RR: 1.03, CI: 0.97–1.10, p = 0.26 and RR: 1.10, CI: 0.98–1.23, p = 0.11, respectively). However, argatroban significantly reduced END (RR: 0.48, CI: 0.30–0.75, p < 0.05) and favored mRS (0–1) with RR:1.22 (CI: 1.01–1.48, p = 0.03). The change in NIHSS score and incidence of mortality, stroke recurrence, intracranial and organ hemorrhage was comparable between the two groups. Subgroup analyses by antiplatelet drug in the intervention and comparison groups confirmed that argatroban showed the most pronounced results when combined with DAPT. While the overall pooled analysis did not demonstrate increased hemorrhagic risk, subgroup analysis restricted to randomized controlled trials revealed a significant increase in composite and intracranial hemorrhage with argatroban. GRADE assessment of RCT-derived evidence indicated very low to high certainty across all outcomes.

Conclusion

Argatroban as an adjunct to antiplatelet therapy did not significantly improve overall functional outcome (mRS 0–2) or reduce composite hemorrhage compared with antiplatelet therapy alone. However it appears safe and may reduce END significantly.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ArginineIschemic StrokePipecolic AcidsPlatelet Aggregation InhibitorsSulfonamidesHumansDrug Therapy, CombinationTreatment Outcome

Stichwörter der Autor:innen

Antiplatelet therapyArgatrobanEarly neurological deteriorationIschemic strokeThrombolysis

Substanzen

argatrobanArgininePipecolic AcidsPlatelet Aggregation InhibitorsSulfonamides

Autor:innen und Institutionen

  • Department of Medicine, Services Institute of Medical Sciences, Lahore, Pakistan.
  • Department of Medicine, Allama Iqbal Medical College, Lahore, Pakistan.
  • Department of Medicine, Foundation University Medical College, Islamabad, Pakistan.
  • Department of Medicine, Rashid Latif Medical College, Lahore, Pakistan.
  • Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
  • Department of Medicine, Continental Medical College, Lahore, Pakistan.

Zitieren

APA

Fatima, S. T., Raza, A., Javed, A., Ijaz, S., Noor, M., Uzair, S. D., Malik, A. R., Mustafa, R. A., & Daim, S. U. R. (2026). Efficacy and Safety of Argatroban as an Adjunct to Antiplatelet Therapy in Ischemic Stroke: An Updated Systematic Review and Meta-analysis. European Journal of Clinical Pharmacology, 82(11). https://doi.org/10.1007/s00228-026-04203-7

Vancouver

Fatima ST, Raza A, Javed A, Ijaz S, Noor M, Uzair SD, et al. Efficacy and Safety of Argatroban as an Adjunct to Antiplatelet Therapy in Ischemic Stroke: An Updated Systematic Review and Meta-analysis. European Journal of Clinical Pharmacology. 2026;82(11). doi:10.1007/s00228-026-04203-7

BibTeX
@article{Fatima2026,
  author = {Fatima, Syeda Takreem and Raza, Ahmed and Javed, Abdullah and Ijaz, Shabnam and Noor, Mishaal and Uzair, Syeda Duaa and Malik, Abdul Raheem and Mustafa, Rana Ali and Daim, Safi Ur Rehman},
  title = {Efficacy and Safety of Argatroban as an Adjunct to Antiplatelet Therapy in Ischemic Stroke: An Updated Systematic Review and Meta-analysis},
  journal = {European Journal of Clinical Pharmacology},
  year = {2026},
  volume = {82},
  number = {11},
  doi = {10.1007/s00228-026-04203-7}
}
Kostenlos starten →